Loading clinical trials…
Loading clinical trials…
Clinical trials
Studies registered on ClinicalTrials.gov whose conditions were reconciled to the cancer taxonomy. Status and phase are as posted by the registrant.
54 studies match
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT07402915 | Drug-drug Interaction Study With AZD5335 and Itraconazole in Participants With Ovarian, Primary Peritoneal, or Fallopian Tube Cancer | recruiting | Phase 1 | 32 | AstraZenecaINDUSTRY | 4 | Sep 29, 2026 | clinicaltrials |
| NCT07293754 | An Early Phase Trial of RPTR-1-201 in Advanced Solid Tumors(RaPTR-101) | recruiting | Phase 1 / Phase 2 | 150 | Repertoire Immune MedicinesINDUSTRY | 4 | Sep 28, 2026 | clinicaltrials |
| NCT07293351 | A Study to Evaluate the Safety, Tolerability, and Efficacy of Pumitamig Alone or in Combination With Other Agents in Participants With Advanced Renal Cell Carcinoma (RCC) (ROSETTA RCC-208) | recruiting | Phase 1 / Phase 2 | 474 | Bristol-Myers SquibbINDUSTRY | 20 | Sep 23, 2026 | clinicaltrials |
| NCT06353386 | Substudy 01A: Safety and Efficacy of Opevesostat (MK-5684)-Based Treatment Combinations or Opevesostat Alone in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-5684-01A) | recruiting | Phase 1 / Phase 2 | 220 | Merck Sharp & Dohme LLCINDUSTRY | 20 | Sep 17, 2026 | clinicaltrials |
| NCT06863272 | A Clinical Study of Ifinatamab Deruxtecan Based Treatment Combinations or as Monotherapy to Treat Metastatic Castrate Resistant Prostate Cancer (mCRPC) (MK-2400-01A/IDeate-Prostate02) | recruiting | Phase 1 / Phase 2 | 360 | Merck Sharp & Dohme LLCINDUSTRY | 19 | Sep 17, 2026 | clinicaltrials |
| NCT07335497 | CR-001 in Adult Participants With Locally Advanced or Metastatic Solid Tumors(ASCEND) | recruiting | Phase 1 / Phase 2 | 290 | Crescent Biopharma, Inc.INDUSTRY | 8 | Sep 10, 2026 | clinicaltrials |
| NCT06253871 | A Phase 1/1b Study of IAM1363 in HER2 Cancers | recruiting | Phase 1 | 383 | Iambic Therapeutics, IncINDUSTRY | 8 | Sep 9, 2026 | clinicaltrials |
| NCT06586515 | MOONRAY-01, A Study of LY3962673 in Participants With KRAS G12D-Mutant Solid Tumors(MOONRAY-01) | recruiting | Phase 1 | 630 | Eli Lilly and CompanyINDUSTRY | 9 | Aug 24, 2026 | clinicaltrials |
| NCT07266428 | A Study of OTP-01, a Dual Paratopic PD-1/VEGFR2 Antibody, in Patients With Advanced Solid Tumors | recruiting | Phase 1 / Phase 2 | 170 | Ottimo Pharma LimitedINDUSTRY | 8 | Aug 13, 2026 | clinicaltrials |
| NCT06330064 | A Study to Evaluate the Efficacy and Safety of Ifinatamab Deruxtecan (I-DXd) in Subjects With Recurrent or Metastatic Solid Tumors (IDeate-PanTumor02) | recruiting | Phase 1 / Phase 2 | 680 | Daiichi SankyoINDUSTRY | 18 | Aug 5, 2026 | clinicaltrials |
| NCT03786081 | Safety and Efficacy of Tisotumab Vedotin Monotherapy & in Combination With Other Cancer Agents in Subjects With Cervical Cancer | terminated | Phase 1 / Phase 2 | 214 | Seagen, a wholly owned subsidiary of PfizerINDUSTRY | 10 | Jul 22, 2026 | clinicaltrials |
| NCT05098132 | Study of STK-012 Alone and With Other Treatments in Patients With Advanced Lung Cancer and Other Cancers(SYNERGY-101) | recruiting | Phase 1 / Phase 2 | 364 | SynthekineINDUSTRY | 4 | Jul 21, 2026 | clinicaltrials |
| NCT05768139 | First-in-Human Study of Tersolisib (STX-478) as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors(PIKALO-1) | recruiting | Phase 1 / Phase 2 | 880 | Eli Lilly and CompanyINDUSTRY | 9 | Jul 7, 2026 | clinicaltrials |
| NCT04421820 | BOLD-100 in Combination With FOLFOX for the Treatment of Advanced Solid Tumours | recruiting | Phase 1 / Phase 2 | 220 | Bold Therapeutics, Inc.INDUSTRY | 7 | May 18, 2026 | clinicaltrials |
| NCT07244341 | A Study of Valemetostat (DS-3201b) in Combination With Darolutamide in Metastatic Castration Resistant Prostate Cancer (mCRPC) | recruiting | Phase 1 | 60 | Daiichi SankyoINDUSTRY | 4 | May 15, 2026 | clinicaltrials |
| NCT07164313 | A Study of ZW251 in Participants With Advanced Solid Tumors | recruiting | Phase 1 | 100 | Zymeworks BC Inc.INDUSTRY | 6 | May 7, 2026 | clinicaltrials |
| NCT06898450 | A Study to Assess the Safety, Tolerability, and Efficacy of NDI-219216 in Patients With Advanced Solid Tumors. | recruiting | Phase 1 / Phase 2 | 134 | Nimbus Wadjet, Inc.INDUSTRY | 8 | May 6, 2026 | clinicaltrials |
| NCT02151019 | Pre-operative 3-DCRT vs IMRT for Locally Advanced Rectal Cancer(TRI-LARC) | terminated | Phase 1 / Phase 2 | 94 | Cancer Trials IrelandNETWORK | 1 | Apr 13, 2026 | clinicaltrials |
| NCT02705859 | Phase Ib/II Trial of coPANlisib in Combination With Trastuzumab in HER2-positive Breast Cancer. (Panther Study)(Panther) | completed | Phase 1 | 26 | Cancer Trials IrelandNETWORK | 1 | Apr 13, 2026 | clinicaltrials |
| NCT02764086 | INTENSE: A Phase I/II Study of INhomogeneous Targeted Dose Escalation in Non-Small CEll Lung Cancer | terminated | Phase 1 / Phase 2 | 6 | Cancer Trials IrelandNETWORK | 1 | Apr 13, 2026 | clinicaltrials |
| NCT04667663 | CPD-DARA in Patients With Relapsed/Refractory Multiple Myeloma.(CPD-DARA) | active not recruiting | Phase 1 | 16 | Cancer Trials IrelandNETWORK | 1 | Apr 13, 2026 | clinicaltrials |
| NCT04262466 | Safety and Efficacy of IMC-F106C as a Single Agent and in Combination With Checkpoint Inhibitors | active not recruiting | Phase 1 / Phase 2 | 410 | Immunocore LtdINDUSTRY | 17 | Mar 6, 2026 | clinicaltrials |
| NCT05527184 | First in Human Study of IMGN151 in Recurrent Gynaecological Cancers | active not recruiting | Phase 1 | 256 | AbbVieINDUSTRY | 10 | Feb 20, 2026 | clinicaltrials |
| NCT05658640 | HEM iSMART-D: Trametinib + Dexamethasone + Chemotherapy in Children With Relapsed or Refractory Hematological Malignancies(HEM-iSMART D) | recruiting | Phase 1 / Phase 2 | 26 | Princess Maxima Center for Pediatric OncologyOTHER | 15 | Sep 16, 2025 | clinicaltrials |
| NCT05745714 | HEM-iSMART-C: Ruxolitinib + Venetoclax + Dexamethasone + Cyclophosphamide and Cytarabine in Pediatric Patients With Relapsed or Refractory Hematological Malignancies(HEM-iSMART C) | recruiting | Phase 1 / Phase 2 | 26 | Princess Maxima Center for Pediatric OncologyOTHER | 14 | Sep 16, 2025 | clinicaltrials |
| NCT05751044 | HEM-iSMART-B: Dasatinib + Venetoclax + Dexamethasone + Cyclophosphamide and Cytarabine in Pediatric Patients With Relapsed or Refractory Hematological Malignancies(HEM-iSMART B) | recruiting | Phase 1 / Phase 2 | 26 | Princess Maxima Center for Pediatric OncologyOTHER | 14 | Sep 16, 2025 | clinicaltrials |
| NCT04042051 | Copanlisib in Combination With T-DM1 in Pretreated Unresectable Locally Advanced or Metastatic HER2-positive Breast Cancer(Panthera) | terminated | Phase 1 | 2 | Cancer Trials IrelandNETWORK | 2 | Jul 22, 2025 | clinicaltrials |
| NCT02123823 | BI 836845 in Estrogen Receptor Positive Metastatic Breast Cancer | completed | Phase 1 | 164 | Boehringer IngelheimINDUSTRY | 10 | Jul 15, 2025 | clinicaltrials |
| NCT05086692 | A Beta-only IL-2 ImmunoTherapY Study(ABILITY-1) | recruiting | Phase 1 / Phase 2 | 115 | Medicenna Therapeutics, Inc.INDUSTRY | 7 | Jul 9, 2025 | clinicaltrials |
| NCT03153280 | Dose Escalation Study of Lithium With Oxaliplatin and Capecitabine in Advanced Oesophago-Gastric or Colorectal Cancer(Lithium) | terminated | Phase 1 | 2 | Cancer Trials IrelandNETWORK | 1 | Jul 8, 2025 | clinicaltrials |
| NCT02637687 | A Study to Test the Safety and Efficacy of the Drug Larotrectinib for the Treatment of Tumors With NTRK-fusion in Children(SCOUT) | active not recruiting | Phase 1 / Phase 2 | 154 | BayerINDUSTRY | 21 | Jun 22, 2025 | clinicaltrials |
| NCT06078813 | Spine SABR - Dose-escalated Stereotactic Ablative Body Radiotherapy (SABR) for Solid Tumour Spine Metastases(Spine-SABR) | recruiting | Phase 1 / Phase 2 | 126 | Cancer Trials IrelandNETWORK | 1 | Apr 30, 2025 | clinicaltrials |
| NCT04630756 | AZD4573 in Novel Combinations With Anti-cancer Agents in Patients With Advanced Blood Cancer | completed | Phase 1 / Phase 2 | 40 | AstraZenecaINDUSTRY | 9 | Apr 9, 2025 | clinicaltrials |
| NCT03215511 | A Study to Test the Safety of the Investigational Drug Selitrectinib in Children and Adults That May Treat Cancer | completed | Phase 1 | 81 | BayerINDUSTRY | 10 | Oct 30, 2024 | clinicaltrials |
| NCT01796171 | A Phase 1/2 Study of Betalutin for Treatment of Relapsed Non-Hodgkin Lymphoma(LYMRIT-37-01) | completed | Phase 1 / Phase 2 | 191 | Nordic NanovectorINDUSTRY | 24 | Jun 21, 2024 | clinicaltrials |
| NCT04625907 | FaR-RMS: An Overarching Study for Children and Adults With Frontline and Relapsed RhabdoMyoSarcoma(FaR-RMS) | recruiting | Phase 1 / Phase 2 | 1,672 | University of BirminghamOTHER | 20 | May 23, 2024 | clinicaltrials |
| NCT03005782 | Study of REGN3767 (Anti-LAG-3) With or Without REGN2810 (Anti-PD1) in Advanced Cancers | completed | Phase 1 | 333 | Regeneron PharmaceuticalsINDUSTRY | 5 | May 1, 2024 | clinicaltrials |
| NCT03980314 | A Study to Compare Nivolumab Drug Product Process D to Nivolumab Drug Product Process C in Participants With Stage IIIa/b/c/d or Stage IV Melanoma After Complete Resection | completed | Phase 1 | 261 | Bristol-Myers SquibbINDUSTRY | 14 | Dec 15, 2023 | clinicaltrials |
| NCT00251433 | GW572016 With Docetaxel and Trastuzumab for the Treatment Of Untreated ErbB2 Over-Expressing Metastatic Breast Cancer | terminated | Phase 1 | 53 | Novartis PharmaceuticalsINDUSTRY | 3 | Mar 31, 2023 | clinicaltrials |
| NCT05156424 | A Comparison of Aerobic and Resistance Exercise to Counteract Treatment Side Effects in Men With Prostate Cancer | unknown | Phase 1 / Phase 2 | 24 | Kira MurphyOTHER | 1 | Dec 14, 2021 | clinicaltrials |
| NCT01787552 | A Phase Ib/II Dose-finding Study to Assess the Safety and Efficacy of LDE225 + INC424 in Patients With MF | completed | Phase 1 / Phase 2 | 50 | Novartis PharmaceuticalsINDUSTRY | 11 | Apr 15, 2020 | clinicaltrials |
| NCT02811822 | A Study to Determine the Efficacy, Safety and Pharmacokinetics of GMI-1271 as Adjunct to Standard of Care for the Treatment of Multiple Myeloma | completed | Phase 1 | 10 | GlycoMimetics IncorporatedINDUSTRY | 4 | Jul 10, 2019 | clinicaltrials |
| NCT02306291 | Study to Determine Safety, Pharmacokinetics and Efficacy of GMI-1271 in Combination With Chemotherapy in AML | completed | Phase 1 / Phase 2 | 91 | GlycoMimetics IncorporatedINDUSTRY | 3 | May 17, 2019 | clinicaltrials |
| NCT02549651 | MEDI4736 Alone and in Combination With Tremelimumab or AZD9150 in Adult Subjects With Relapsed/Refractory DLBCL (D4190C00023) | completed | Phase 1 | 32 | MedImmune LLCINDUSTRY | 4 | Feb 27, 2019 | clinicaltrials |
| NCT01428492 | Ph 1b Study to Evaluate GSK2110183 in Combination With Bortezomib and Dexamethasone in Subjects With Multiple Myeloma(PKB115125) | completed | Phase 1 | 90 | NovartisINDUSTRY | 5 | Aug 8, 2018 | clinicaltrials |
| NCT02955810 | Cyclophosphamide-Bortezomib-Dexamethasone (CyBorD) With Daratumumab (DARA)(CyBorD-Dara) | unknown | Phase 1 | 18 | National University of Ireland, Galway, IrelandOTHER | 1 | Mar 29, 2018 | clinicaltrials |
| NCT01172860 | Endoscopic Treatment of Inoperable Colorectal Cancer With the EndoVe System(CCEE EndoVe) | completed | Phase 1 | 10 | Mercy University Hospital, Cork, IrelandOTHER | 1 | Nov 9, 2017 | clinicaltrials |
| NCT00753207 | Lapatinib and Epirubicin in Treating Patients With Metastatic Breast Cancer. ICORG 06-30 | completed | Phase 1 | 10 | Cancer Trials IrelandNETWORK | 1 | Feb 15, 2016 | clinicaltrials |
| NCT01495884 | The Myocet/Lapatinib Study. ICORG 10-03, V5 | terminated | Phase 1 / Phase 2 | 11 | Cancer Trials IrelandNETWORK | 1 | Oct 26, 2015 | clinicaltrials |
| NCT00360854 | Erlotinib Alone or in Combination With Radiation Therapy in Treating Young Patients With Refractory or Relapsed Malignant Brain Tumors or Newly Diagnosed Brain Stem Glioma | unknown | Phase 1 | 48 | Children's Cancer and Leukaemia GroupOTHER | 2 | Sep 20, 2013 | clinicaltrials |
Data updated 1 hour agoSource updated unknownsource: clinicaltrials